Amphastar Pharmaceuticals (AMPH) Other Non-Current Liabilities (2014 - 2026)

Amphastar Pharmaceuticals' Other Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $5.9 million for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities fell 75.73% year-over-year to $5.9 million in Q1 2026; TTM through Mar 2026 was $5.9 million, a 75.73% decrease from a year earlier, with the FY2025 full-year figure at $5.9 million, down 71.71% from the prior year.
• Other Non-Current Liabilities held at $5.9 million in Q1 2026 per AMPH's latest filing, from $5.9 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $27.0 million in Q3 2024 and bottomed at $5.9 million in Q4 2025.
• The 5-year median for Other Non-Current Liabilities is $14.2 million (2022), against an average of $13.2 million.
• Across the five-year window, Other Non-Current Liabilities jumped 274.21% in 2024 and sank 75.73% in 2026, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $7.2 million in 2022, then retreated by 16.04% to $6.1 million in 2023, then surged by 245.29% to $20.9 million in 2024, then tumbled by 71.71% to $5.9 million in 2025, then changed by 0.0% to $5.9 million in 2026.
• Per Business Quant, the three latest AMPH Other Non-Current Liabilities figures stand at $5.9 million (Q1 2026), $5.9 million (Q4 2025), and $7.0 million (Q3 2025).